Attovia Therapeutics Inc. (ATTO)
NASDAQ: ATTOHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ATTO stock chart
Technical analysisKey statistics
All statistics- Market cap
- $690.26M
- EPS (TTM)
- -$5.53
- Dividend yield
- None
- 52-week range
- 12.94 – 28.00
- Day range
- 14.80 – 15.46
- Volume / Avg
- 372.22K / 337.27K
- Beta
- —
- Shares outstanding
- 45.71M
- Next earnings
- Dec 2, 2026
52-week range
ATTO stock today
Shares of Attovia Therapeutics (ATTO) finished lower on Nov 20 at $15.10, a drop of 3.08% or $0.48 per share, versus the S&P 500's 3.70% decline. At this level, ATTO sits near the bottom of its 52-week range of $12.94 to $28.00: 46.1% below the high, set on Sep 8, 2026 and 16.7% above the low. Attovia Therapeutics has posted a net loss over the last twelve months (EPS of -$5.53), so its P/E ratio is not meaningful.
The company is scheduled to report Sep/2026 results on Dec 2; analysts expect EPS of -$0.74.
Summary generated from market data by MetaCap's automated system. Methodology
About Attovia Therapeutics
Company profileAttovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments. The company's products include ATTO-1310, a novel ATTOBODY-based Fc-fusion protein therapeutic that inhibits IL-31; developed for the treatment of chronic pruritic diseases such as CPUO, high-itch AD, cholestatic pruritus, and CKD-aP; ATTO-2306, an ATTOBODY-based, half-life-extended immunoglobulin G (IgG)-fusion protein therapeutic that inhibits IL-13 and IL-31; developed for the treatment of AD and other immune-mediated skin diseases, such as CSU and PN; and ATTO-1091, a trispecific ATTOBODY-based Fc-fusion protein therapeutic that inhibits TL1A, IL-23, and integrin a4ß7; developed for IBD a chronic immune-mediated condition characterized by persistent inflammation of the gastrointestinal tract, includes ulcerative colitis (UC) and crohn's disease (CD).
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Tao Fu M.B.A., M.S.
- Headquarters
- San Carlos, CA
- Employees
- 50
- IPO year
- 2026
- Website
- attovia.com
Analyst forecast
ForecastConsensus (5 analysts)
strong_buy
Avg. price target
$43.20+186.09%
- Strong buy 2
- Buy 3
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Dec 2, 2026
- EPS estimate
- $-0.74
- Last reported (Sep/2026)
- Dec 2, 2026
- EPS actual vs est.
- $-0.76 vs $-0.74
- Surprise
- -2.70%
ATTO news
All ATTO news- Attovia Therapeutics, Inc. GAAP EPS of -$0.76Seeking Alpha
- Attovia Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate UpdateGlobeNewswire
- Attovia Therapeutics Announces Positive Topline 12-Week Results from Phase 1b Study of ATTO-1310 in Patients with Chronic Pruritus and High-Itch Atopic DermatitisGlobeNewswire
- Attovia Therapeutics Becomes Oversold (ATTO)Nasdaq
Attovia Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| SLDBSolid Biosciences Inc. | 6.25 | -2.95% | $697.57M | vs ATTO |
| AURAAura Biosciences Inc. | 6.87 | -1.58% | $714.99M | vs ATTO |
| GLUEMonte Rosa Therapeutics Inc. | 8.64 | -3.03% | $738.29M | vs ATTO |
| IAMIambic Therapeutics Inc. | 13.11 | -8.06% | $621.42M | vs ATTO |
| MGTXMeiraGTx Holdings plc | 7.98 | -1.97% | $779.89M | vs ATTO |
| SRZNSurrozen Inc. | 28.46 | -7.21% | $596.40M | vs ATTO |
| PRMEPrime Medicine Inc. | 3.55 | -7.55% | $791.62M | vs ATTO |
| CGEMCullinan Therapeutics Inc. | 8.89 | -1.98% | $577.15M | vs ATTO |
Indexes, lists and sector
Attovia Therapeutics stock FAQ
What is Attovia Therapeutics's stock price today?
ATTO last traded at $15.10 as of Nov 20, 4:00 PM EST, down 3.08% on the day. Prices are delayed at least 15 minutes.
When is Attovia Therapeutics's next earnings date?
Attovia Therapeutics is expected to report earnings on Wednesday, December 2, 2026. Analysts expect EPS of $-0.74.
Who is Attovia Therapeutics's CEO?
Mr. Tao Fu M.B.A., M.S. is the chief executive officer of Attovia Therapeutics Inc., which has about 50 employees.
What is the ATTO 52-week high?
The 52-week high for ATTO is $28.00 and the 52-week low is $12.94. The stock is currently 46.1% below its high.